CR20240014A - Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 - Google Patents

Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Info

Publication number
CR20240014A
CR20240014A CR20240014A CR20240014A CR20240014A CR 20240014 A CR20240014 A CR 20240014A CR 20240014 A CR20240014 A CR 20240014A CR 20240014 A CR20240014 A CR 20240014A CR 20240014 A CR20240014 A CR 20240014A
Authority
CR
Costa Rica
Prior art keywords
pyrazoles
substituted pyrimidinyl
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
CR20240014A
Other languages
English (en)
Inventor
Natasja Brooijmans
Steven Mark Wenglowsky
Richard Vargas
Emanuele Perola
Philip D Ramsden
Douglas Wilson
Jr Neil Bifulco
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CR20240014A publication Critical patent/CR20240014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona un compuesto representado por la fórmula estructural (I): (I) (I), o una sal farmacéuticamente aceptable de este útil para tratar el cáncer.
CR20240014A 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 CR20240014A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211426P 2021-06-16 2021-06-16
US202263327474P 2022-04-05 2022-04-05
PCT/US2022/033576 WO2022266190A1 (en) 2021-06-16 2022-06-15 Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
CR20240014A true CR20240014A (es) 2024-05-07

Family

ID=82694316

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240014A CR20240014A (es) 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Country Status (17)

Country Link
US (1) US20240287040A1 (es)
EP (1) EP4355742A1 (es)
JP (1) JP2024523892A (es)
KR (1) KR20240022609A (es)
AU (1) AU2022293861A1 (es)
BR (1) BR112023026538A2 (es)
CA (1) CA3224189A1 (es)
CL (1) CL2023003758A1 (es)
CO (1) CO2024000221A2 (es)
CR (1) CR20240014A (es)
DO (1) DOP2023000277A (es)
EC (1) ECSP24003566A (es)
IL (1) IL309013A (es)
MX (1) MX2023015245A (es)
PE (1) PE20240769A1 (es)
SA (1) SA523451905B1 (es)
WO (1) WO2022266190A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
KR20250121114A (ko) 2022-12-16 2025-08-11 아스트라제네카 아베 2,6,9-삼치환된 퓨린
WO2025117682A1 (en) 2023-12-01 2025-06-05 Blueprint Medicines Corporation Cyclin-dependent kinase 2 degraders
WO2025188779A1 (en) 2024-03-04 2025-09-12 Blueprint Medicines Corporation Cdk2 inhibitors for treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US20020111353A1 (en) * 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2005524672A (ja) * 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1706400A1 (en) * 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
WO2016193939A1 (en) * 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors

Also Published As

Publication number Publication date
JP2024523892A (ja) 2024-07-02
AU2022293861A1 (en) 2024-01-04
MX2023015245A (es) 2024-01-19
ECSP24003566A (es) 2024-04-30
KR20240022609A (ko) 2024-02-20
WO2022266190A1 (en) 2022-12-22
IL309013A (en) 2024-01-01
US20240287040A1 (en) 2024-08-29
CA3224189A1 (en) 2022-12-22
CL2023003758A1 (es) 2024-07-12
CO2024000221A2 (es) 2024-01-25
EP4355742A1 (en) 2024-04-24
BR112023026538A2 (pt) 2024-03-05
DOP2023000277A (es) 2024-03-28
SA523451905B1 (ar) 2025-06-22
PE20240769A1 (es) 2024-04-17

Similar Documents

Publication Publication Date Title
MX2024000230A (es) Inhibidores de cdk2.
PH12022551574A1 (en) Egfr inhibitors
PH12021552805A1 (en) Cdk inhibitors
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MY208377A (en) Compounds
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MX2025012153A (es) Inhibidores de cdk2
MX2024012267A (es) Inhibidores de egfr
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2021015418A (es) Terapia inmunooncologica.
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors
EP4397366A3 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
ZA202213318B (en) Antifungal agent for use in humans
UY39662A (es) Inhibidores de egfr
EP4649947A3 (en) Methods for treating against viruses
ZA202100661B (en) Borate of azetidine derivative
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7
AR132411A1 (es) Inhibidores de cdk2